KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities (2018 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Other Non-Current Liabilities data on record, last reported at $19.1 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 5.99% year-over-year to $19.1 million; the TTM value through Dec 2025 reached $19.1 million, up 5.99%, while the annual FY2025 figure was $19.1 million, 5.99% up from the prior year.
  • Other Non-Current Liabilities reached $19.1 million in Q4 2025 per ACAD's latest filing, up from $13.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $28.5 million in Q2 2025 and bottomed at $3.6 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $11.3 million, with a median of $10.3 million recorded in 2023.
  • The widest YoY moves for Other Non-Current Liabilities: up 130.93% in 2025, down 9.35% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $7.0 million in 2021, then grew by 29.0% to $9.1 million in 2022, then skyrocketed by 66.93% to $15.1 million in 2023, then rose by 19.21% to $18.1 million in 2024, then rose by 5.99% to $19.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $19.1 million in Q4 2025, $13.9 million in Q3 2025, and $28.5 million in Q2 2025.